Newly formed Advisory Board to advise on cancer screening methods and
mitochondrial DNA-based disease detection
OMAHA, Neb., Jan. 17 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today announced that it has formed a Scientific Advisory Board to advise the Company on the latest developments and scientific opportunities in cancer detection screening and mitochondrial disease diagnosis. The initial members of the board are to include Christopher Corless M.D., Ph.D. of Oregon Health & Science University, Pasi Janne M.D., Ph.D. of the Dana Farber Cancer Institute, Robert Naviaux M.D., Ph.D. of the University of California at San Diego, Bruce H. Cohen M.D. of the Cleveland Clinic, and Dr. Keshav Singh Ph.D. of the Roswell Park Cancer Institute.
Craig Tuttle, Transgenomic's President and Chief Executive Officer, commented, "The formation of this Scientific Advisory Board strengthens Transgenomic's recent emphasis on biomarker development and intellectual property for our clinical reference and pharmacogenomics labs. Their input and leadership will be instrumental in guiding our future product and service offering development efforts. Drs. Janne and Corless bring tremendous expertise in cancer screening and treatment, particularly in receptor tyrosine kinase involvement in cancer, while Drs. Naviaux, Cohen and Singh join to advise us on the many opportunities that exist around mitochondria DNA-based diagnostics in many disease states including diabetes, Parkinson's and cancer. We expect our collaboration with these distinguished researchers will help us to better evaluate both internal and external opportunities and build on our existing expertise and diagnostic offerings in our growing Molecular Diagnostics and Pharmacogenomics Laboratories."
Transgenomic is a global biotechnology company that provides unique
products and services for automated high sensitivity genetic variat
|SOURCE Transgenomic, Inc.|
Copyright©2008 PR Newswire.
All rights reserved